Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 18/20 | 0.49 |
| ▸ | TPSB2 | P20231 | 7/20 | 0.42 |
| ▸ | F11 | P03951 | 6/20 | 0.42 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853012 | 1.00 | CFD (0.49) | CFDTPSB2F11PLAUPLG | |
| SCHEMBL23219202 | 0.92 | CFD (0.52) | CFDTPSB2F11PLAUPLG | |
| SCHEMBL29852834 | 0.92 | CFD (0.52) | CFDTPSB2F11PLAUPLG | |
| SCHEMBL29852536 | 0.91 | CFD (0.51) | CFDTPSB2F11PLAUPLG | |
| SCHEMBL23219212 | 0.91 | CFD (0.51) | CFDTPSB2F11PLAUPLG | |
| SCHEMBL23219200 | 0.91 | CFD (0.48) | CFDTPSB2F11PLAUPLG | |
| SCHEMBL29852862 | 0.91 | CFD (0.48) | CFDTPSB2F11PLAUPLG | |
| SCHEMBL23219008 | 0.90 | CFD (0.50) | CFDTPSB2F11PLAUPLG | |
| SCHEMBL29852893 | 0.90 | CFD (0.50) | CFDTPSB2F11PLAUPLG | |
| SCHEMBL23218079 | 0.88 | CFD (0.52) | CFDTPSB2F11PLAUPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |